Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

The meeting of the European Radiation Research Society (ERRS) was held in Sicily, Italy between the 21-24 September and was attended by Nathalie LövgrenSalome Paillas and Ester Hammond from the Department.

Congratulations to Nathalie who was selected for a Young Investigators Award (YIA) and received the award from ERRS president Georgia Terzoudi. Nathalie, a DPhil student from Kristoffer Petersson’s group, presented her work on “In Silico Comparisons of FLASH Proton Therapy versus Conventional Dose Rate Treatment Plans”.

Nathalie Lovgren receives her Young Investigator Award from ERRS president Georgia TerzoudiNathalie Lovgren receives her Young Investigator Award from ERRS president Georgia Terzoudi

 

Salome Paillas - also from Kristoffer's lab -  was selected to give a short talk focused on “FLASH irradiation reduces radiation-induced skin and lung toxicity while being as efficient as conventional irradiation in antitumor response”. FLASH radiotherapy (FLASH-RT) is a new technique, involving treatment of tumours at ultra-high dose rates, which has been shown to reduce normal tissue from radiation-induced toxicity, whilst equalling the anti-tumour effect of conventional dose rate radiotherapy (CONV-RT). Salome outlined how her group colleagues performed a dose-response study in mice comparing the effect of FLASH-RT versus CONV-RT on skin and lung toxicity as well as tumour response in a lung cancer xenograft model.

 

Salome Paillas presents her talk entitled 'FLASH irradiation reduces radiation-induced skin and lung toxicity while being as efficient as conventional irradiation in antitumor response'Salome Paillas presents her talk entitled 'FLASH irradiation reduces radiation-induced skin and lung toxicity while being as efficient as conventional irradiation in antitumor response'

 

Ester Hammond, who is part of the ERRS committee, gave a keynote lecture on “Targeting radiobiological hypoxia to improve radiotherapy response”. Key to the DNA damage induced by radiation is the presence of oxygen. In conditions of low oxygen (radiobiological hypoxia) significantly less DNA damage is induced by radiation leading to therapy resistance and disease progression. Regions of hypoxia occur in most solid tumours and, although the degree of hypoxia (how little oxygen) varies, these include areas of radiobiological hypoxia. The focus of Ester's work is the mechanistic investigation of the response to radiobiological hypoxia with a view to identifying therapeutic strategies to improve radiotherapy response. In particular, Ester's group has focused on the DNA damage response induced in radiobiological hypoxia which is unusual as it is dependent on replication stress and occurs in the absence of detectable DNA damage. Recently, the group has implicated the unfolded protein response as part of the response to hypoxia-induced replication stress.

 

Professor Ester Hammond delivers her keynote seminar entitled 'Targeting radiobiological hypoxia to improve radiotherapy response'Professor Ester Hammond delivers her keynote seminar entitled 'Targeting radiobiological hypoxia to improve radiotherapy response'

 

Congratulations to Nathalie on her award, and well done to Salome and Ester on their presentations. If you would like to find out more about the European Radiation Research Society, you can visit the ERRS website.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.